Loading...
XCSEHLUN A
Market cap4.47bUSD
Dec 20, Last price  
32.95DKK
1D
0.76%
1Q
-17.52%
Name

H. Lundbeck

Chart & Performance

D1W1MN
XCSE:HLUN A chart
P/E
13.96
P/S
1.61
EPS
2.36
Div Yield, %
1.80%
Shrs. gr., 5y
37.93%
Rev. gr., 5y
2.18%
Revenues
19.91b
+9.13%
9,732,900,0009,069,800,0009,221,000,00010,984,900,00011,281,800,00013,747,000,00014,765,000,00016,007,000,00014,802,000,00015,258,000,00013,468,000,00014,594,000,00015,634,000,00017,234,000,00017,875,000,00017,358,000,00017,667,000,00016,299,000,00018,246,000,00019,912,000,000
Net income
2.29b
+19.52%
1,708,700,0002,923,400,0002,158,700,0003,353,500,0002,736,200,0002,007,000,0002,466,000,0002,282,000,0001,107,000,000855,000,000-153,000,000-5,694,000,0001,211,000,0002,624,000,0003,907,000,0002,667,000,0001,581,000,0001,318,000,0001,916,000,0002,290,000,000
CFO
4.08b
+15.94%
2,677,800,0002,071,500,0001,394,000,0002,704,800,0002,780,200,0003,034,000,0003,265,000,0003,624,000,0002,112,000,0003,760,000,0001,610,000,000197,000,0003,126,000,0004,045,000,0005,981,000,0002,609,000,0003,837,000,0002,272,000,0003,519,000,0004,080,000,000
Dividend
Mar 21, 20240.7 DKK/sh
Earnings
Mar 20, 2025

Profile

H. Lundbeck A/S, a biopharmaceutical company, engages in the research, development, production, and sale of pharmaceuticals for the treatment of psychiatric and neurological disorders in Europe, North America, and internationally. The company's principal products include Abilify Maintena for schizophrenia; Brintellix/Trintellix to treat depression; Northera for the treatment of symptomatic neurogenic orthostatic hypotension; Vyepti for migraine prevention; and Rexulti/Rxulti to treat depression/schizophrenia. It also provides Azilect for treating Parkinson's disease; Cipralex/Lexapro for depression; Ebixa to treat Alzheimer's disease; Onfi for Lennox-Gastaut syndrome; Sabril for treating epilepsy; and Xenazine for chorea associated with Huntington's disease, as well as other products. The company sells its products primarily to distributors of pharmaceuticals, pharmacies, and hospitals. It has a partnership agreement with Verantos to focus on a study to enable real-world evidence in support of migraine therapy; and collaboration with Rgenta Therapeutics, Inc. The company was founded in 1915 and is headquartered in Valby, Denmark.
URL
https://www.lundbeck.com/
IPO date
Jan 01, 1999
Employees
5,600
Domiciled in
DK
Incorporated in
DK

Valuation

Title
DKK in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑122014‑12
Income
Revenues
19,912,000
9.13%
18,246,000
11.95%
16,299,000
-7.74%
Cost of revenue
16,717,000
15,394,000
14,289,000
Unusual Expense (Income)
NOPBT
3,195,000
2,852,000
2,010,000
NOPBT Margin
16.05%
15.63%
12.33%
Operating Taxes
703,000
558,000
263,000
Tax Rate
22.00%
19.57%
13.08%
NOPAT
2,492,000
2,294,000
1,747,000
Net income
2,290,000
19.52%
1,916,000
45.37%
1,318,000
-16.64%
Dividends
(576,000)
(397,000)
(497,000)
Dividend yield
2.02%
1.67%
Proceeds from repurchase of equity
(43,000)
(45,000)
(34,000)
BB yield
0.15%
0.19%
Debt
Debt current
86,000
88,000
86,000
Long-term debt
4,502,000
5,974,000
5,775,000
Deferred revenue
Other long-term liabilities
1,024,000
831,000
872,000
Net debt
(422,000)
2,273,000
3,391,000
Cash flow
Cash from operating activities
4,080,000
3,519,000
2,272,000
CAPEX
(277,000)
(820,000)
(612,000)
Cash from investing activities
(498,000)
(1,892,000)
(610,000)
Cash from financing activities
(2,085,000)
(387,000)
(3,336,000)
FCF
5,996,000
(1,304,000)
1,693,000
Balance
Cash
5,010,000
3,421,000
2,279,000
Long term investments
368,000
191,000
Excess cash
4,014,400
2,876,700
1,655,050
Stockholders' equity
22,045,000
20,779,000
18,279,000
Invested Capital
23,205,600
23,777,300
22,298,950
ROIC
10.61%
9.96%
7.79%
ROCE
10.83%
9.90%
7.91%
EV
Common stock shares outstanding
992,235
992,867
794,644
Price
28.70
20.18%
23.88
 
Market cap
28,477,144
20.11%
23,709,664
 
EV
28,055,144
25,982,664
EBITDA
5,207,000
4,663,000
3,720,000
EV/EBITDA
5.39
5.57
Interest
97,000
103,000
153,000
Interest/NOPBT
3.04%
3.61%
7.61%